

Global Biosimilar Bevacizuma Market Growth 2026-2032

<https://marketpublishers.com/r/GFA4185551B2EN.html>

Date: July 2026

Pages: 136

Price: US\$ 3,660.00 (Single User License)

ID: GFA4185551B2EN

Abstracts

The global Biosimilar Bevacizuma market size is predicted to grow from US\$ 1697 million in 2025 to US\$ 3150 million in 2032; it is expected to grow at a CAGR of 9.4% from 2026 to 2032.

Bevacizumab is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers. Like generics, biosimilars have similar safety and effectiveness as their original (reference) medication. But they usually cost less.

Market CAGR for biosimilar bevacizumab is being driven by the advancing product innovation. Advancing product innovation in the biosimilar bevacizumab market entails leveraging cutting-edge technologies and research methodologies to develop high-quality alternatives to the original drug. This involves refining manufacturing processes, enhancing therapeutic efficacy, and ensuring regulatory compliance. By driving innovation, companies can expand market access, improve patient outcomes, and foster competition, ultimately leading to increased affordability and accessibility of this critical biologic therapy.

LP Information, Inc. (LPI) ' newest research report, the "Biosimilar Bevacizuma Industry Forecast" looks at past sales and reviews total world Biosimilar Bevacizuma sales in 2025, providing a comprehensive analysis by region and market sector of projected Biosimilar Bevacizuma sales for 2026 through 2032. With Biosimilar Bevacizuma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Biosimilar Bevacizuma industry.

This Insight Report provides a comprehensive analysis of the global Biosimilar Bevacizuma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilar Bevacizuma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Biosimilar Bevacizuma market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar Bevacizuma and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar Bevacizuma.

This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar Bevacizuma market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Avastin

Mvasi

Zirabev

Aybintio

Others

Segmentation by Application:

Colorectal Cancer

Non-Small Cell Lung Cancer

Glioblastoma

Renal Cell Carcinoma

Cervical Cancer

Ovarian Cancer

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Amgen

AryoGen

Pharmed

Biothera

Boehringer Ingelheim

Centus Biotherapeutics

Henlius Biotech

Innovent Biologics

Mylan

mAbxience

Outlook Therapeutics

Pfizer

Prestige Biopharma

Roche

Samsung Bio

TOT Biopharm

Key Questions Addressed in this Report

What is the 10-year outlook for the global Biosimilar Bevacizuma market?

What factors are driving Biosimilar Bevacizuma market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Biosimilar Bevacizuma market opportunities vary by end market size?

How does Biosimilar Bevacizuma break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Biosimilar Bevacizuma Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Biosimilar Bevacizuma by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Biosimilar Bevacizuma by Country/Region, 2021, 2025 & 2032
- 2.2 Biosimilar Bevacizuma Segment by Type
 - 2.2.1 Avastin
 - 2.2.2 Mvasi
 - 2.2.3 Zirabev
 - 2.2.4 Aybintio
 - 2.2.5 Others
 - 2.2.6 Biosimilar Bevacizuma Sales by Type
 - 2.2.6.1 Global Biosimilar Bevacizuma Sales Market Share by Type (2021-2026)
 - 2.2.6.2 Global Biosimilar Bevacizuma Revenue and Market Share by Type (2021-2026)
 - 2.2.6.3 Global Biosimilar Bevacizuma Sale Price by Type (2021-2026)
- 2.3 Biosimilar Bevacizuma Segment by Application
 - 2.3.1 Colorectal Cancer
 - 2.3.2 Non-Small Cell Lung Cancer
 - 2.3.3 Glioblastoma
 - 2.3.4 Renal Cell Carcinoma
 - 2.3.5 Cervical Cancer
 - 2.3.6 Ovarian Cancer

2.3.7 Others

2.3.8 Biosimilar Bevacizuma Sales by Application

2.3.8.1 Global Biosimilar Bevacizuma Sale Market Share by Application (2021-2026)

2.3.8.2 Global Biosimilar Bevacizuma Revenue and Market Share by Application (2021-2026)

2.3.8.3 Global Biosimilar Bevacizuma Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Biosimilar Bevacizuma Breakdown Data by Company

3.1.1 Global Biosimilar Bevacizuma Annual Sales by Company (2021-2026)

3.1.2 Global Biosimilar Bevacizuma Sales Market Share by Company (2021-2026)

3.2 Global Biosimilar Bevacizuma Annual Revenue by Company (2021-2026)

3.2.1 Global Biosimilar Bevacizuma Revenue by Company (2021-2026)

3.2.2 Global Biosimilar Bevacizuma Revenue Market Share by Company (2021-2026)

3.3 Global Biosimilar Bevacizuma Sale Price by Company

3.4 Key Manufacturers Biosimilar Bevacizuma Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Biosimilar Bevacizuma Product Location Distribution

3.4.2 Players Biosimilar Bevacizuma Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR BIOSIMILAR BEVACIZUMA BY GEOGRAPHIC REGION

4.1 World Historic Biosimilar Bevacizuma Market Size by Geographic Region (2021-2026)

4.1.1 Global Biosimilar Bevacizuma Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Biosimilar Bevacizuma Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Biosimilar Bevacizuma Market Size by Country/Region (2021-2026)

4.2.1 Global Biosimilar Bevacizuma Annual Sales by Country/Region (2021-2026)

4.2.2 Global Biosimilar Bevacizuma Annual Revenue by Country/Region (2021-2026)

4.3 Americas Biosimilar Bevacizuma Sales Growth

4.4 APAC Biosimilar Bevacizuma Sales Growth

4.5 Europe Biosimilar Bevacizuma Sales Growth

4.6 Middle East & Africa Biosimilar Bevacizuma Sales Growth

5 AMERICAS

5.1 Americas Biosimilar Bevacizuma Sales by Country

5.1.1 Americas Biosimilar Bevacizuma Sales by Country (2021-2026)

5.1.2 Americas Biosimilar Bevacizuma Revenue by Country (2021-2026)

5.2 Americas Biosimilar Bevacizuma Sales by Type (2021-2026)

5.3 Americas Biosimilar Bevacizuma Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Biosimilar Bevacizuma Sales by Region

6.1.1 APAC Biosimilar Bevacizuma Sales by Region (2021-2026)

6.1.2 APAC Biosimilar Bevacizuma Revenue by Region (2021-2026)

6.2 APAC Biosimilar Bevacizuma Sales by Type (2021-2026)

6.3 APAC Biosimilar Bevacizuma Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Biosimilar Bevacizuma by Country

7.1.1 Europe Biosimilar Bevacizuma Sales by Country (2021-2026)

7.1.2 Europe Biosimilar Bevacizuma Revenue by Country (2021-2026)

7.2 Europe Biosimilar Bevacizuma Sales by Type (2021-2026)

7.3 Europe Biosimilar Bevacizuma Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Biosimilar Bevacizuma by Country

8.1.1 Middle East & Africa Biosimilar Bevacizuma Sales by Country (2021-2026)

8.1.2 Middle East & Africa Biosimilar Bevacizuma Revenue by Country (2021-2026)

8.2 Middle East & Africa Biosimilar Bevacizuma Sales by Type (2021-2026)

8.3 Middle East & Africa Biosimilar Bevacizuma Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Biosimilar Bevacizuma

10.3 Manufacturing Process Analysis of Biosimilar Bevacizuma

10.4 Industry Chain Structure of Biosimilar Bevacizuma

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Biosimilar Bevacizuma Distributors

11.3 Biosimilar Bevacizuma Customer

12 WORLD FORECAST REVIEW FOR BIOSIMILAR BEVACIZUMA BY

GEOGRAPHIC REGION

12.1 Global Biosimilar Bevacizuma Market Size Forecast by Region

12.1.1 Global Biosimilar Bevacizuma Forecast by Region (2027-2032)

12.1.2 Global Biosimilar Bevacizuma Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Biosimilar Bevacizuma Forecast by Type (2027-2032)

12.7 Global Biosimilar Bevacizuma Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Amgen

13.1.1 Amgen Company Information

13.1.2 Amgen Biosimilar Bevacizuma Product Portfolios and Specifications

13.1.3 Amgen Biosimilar Bevacizuma Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Amgen Main Business Overview

13.1.5 Amgen Latest Developments

13.2 AryoGen

13.2.1 AryoGen Company Information

13.2.2 AryoGen Biosimilar Bevacizuma Product Portfolios and Specifications

13.2.3 AryoGen Biosimilar Bevacizuma Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 AryoGen Main Business Overview

13.2.5 AryoGen Latest Developments

13.3 Pharmed

13.3.1 Pharmed Company Information

13.3.2 Pharmed Biosimilar Bevacizuma Product Portfolios and Specifications

13.3.3 Pharmed Biosimilar Bevacizuma Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 Pharmed Main Business Overview

13.3.5 Pharmed Latest Developments

13.4 Biothera

13.4.1 Biothera Company Information

13.4.2 Biothera Biosimilar Bevacizuma Product Portfolios and Specifications

13.4.3 Biothera Biosimilar Bevacizuma Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 Biothera Main Business Overview

13.4.5 Biothera Latest Developments

13.5 Boehringer Ingelheim

13.5.1 Boehringer Ingelheim Company Information

13.5.2 Boehringer Ingelheim Biosimilar Bevacizuma Product Portfolios and Specifications

13.5.3 Boehringer Ingelheim Biosimilar Bevacizuma Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 Boehringer Ingelheim Main Business Overview

13.5.5 Boehringer Ingelheim Latest Developments

13.6 Centus Biotherapeutics

13.6.1 Centus Biotherapeutics Company Information

13.6.2 Centus Biotherapeutics Biosimilar Bevacizuma Product Portfolios and Specifications

13.6.3 Centus Biotherapeutics Biosimilar Bevacizuma Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 Centus Biotherapeutics Main Business Overview

13.6.5 Centus Biotherapeutics Latest Developments

13.7 Henlius Biotech

13.7.1 Henlius Biotech Company Information

13.7.2 Henlius Biotech Biosimilar Bevacizuma Product Portfolios and Specifications

13.7.3 Henlius Biotech Biosimilar Bevacizuma Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 Henlius Biotech Main Business Overview

13.7.5 Henlius Biotech Latest Developments

13.8 Innovent Biologics

13.8.1 Innovent Biologics Company Information

13.8.2 Innovent Biologics Biosimilar Bevacizuma Product Portfolios and Specifications

13.8.3 Innovent Biologics Biosimilar Bevacizuma Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Innovent Biologics Main Business Overview

13.8.5 Innovent Biologics Latest Developments

13.9 Mylan

13.9.1 Mylan Company Information

13.9.2 Mylan Biosimilar Bevacizuma Product Portfolios and Specifications

13.9.3 Mylan Biosimilar Bevacizuma Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.9.4 Mylan Main Business Overview
- 13.9.5 Mylan Latest Developments
- 13.10 mAbxience
 - 13.10.1 mAbxience Company Information
 - 13.10.2 mAbxience Biosimilar Bevacizuma Product Portfolios and Specifications
 - 13.10.3 mAbxience Biosimilar Bevacizuma Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.10.4 mAbxience Main Business Overview
 - 13.10.5 mAbxience Latest Developments
- 13.11 Outlook Therapeutics
 - 13.11.1 Outlook Therapeutics Company Information
 - 13.11.2 Outlook Therapeutics Biosimilar Bevacizuma Product Portfolios and Specifications
 - 13.11.3 Outlook Therapeutics Biosimilar Bevacizuma Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.11.4 Outlook Therapeutics Main Business Overview
 - 13.11.5 Outlook Therapeutics Latest Developments
- 13.12 Pfizer
 - 13.12.1 Pfizer Company Information
 - 13.12.2 Pfizer Biosimilar Bevacizuma Product Portfolios and Specifications
 - 13.12.3 Pfizer Biosimilar Bevacizuma Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.12.4 Pfizer Main Business Overview
 - 13.12.5 Pfizer Latest Developments
- 13.13 Prestige Biopharma
 - 13.13.1 Prestige Biopharma Company Information
 - 13.13.2 Prestige Biopharma Biosimilar Bevacizuma Product Portfolios and Specifications
 - 13.13.3 Prestige Biopharma Biosimilar Bevacizuma Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.13.4 Prestige Biopharma Main Business Overview
 - 13.13.5 Prestige Biopharma Latest Developments
- 13.14 Roche
 - 13.14.1 Roche Company Information
 - 13.14.2 Roche Biosimilar Bevacizuma Product Portfolios and Specifications
 - 13.14.3 Roche Biosimilar Bevacizuma Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.14.4 Roche Main Business Overview
 - 13.14.5 Roche Latest Developments

13.15 Samsung Bio

13.15.1 Samsung Bio Company Information

13.15.2 Samsung Bio Biosimilar Bevacizuma Product Portfolios and Specifications

13.15.3 Samsung Bio Biosimilar Bevacizuma Sales, Revenue, Price and Gross Margin (2021-2026)

13.15.4 Samsung Bio Main Business Overview

13.15.5 Samsung Bio Latest Developments

13.16 TOT Biopharm

13.16.1 TOT Biopharm Company Information

13.16.2 TOT Biopharm Biosimilar Bevacizuma Product Portfolios and Specifications

13.16.3 TOT Biopharm Biosimilar Bevacizuma Sales, Revenue, Price and Gross Margin (2021-2026)

13.16.4 TOT Biopharm Main Business Overview

13.16.5 TOT Biopharm Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Biosimilar Bevacizuma Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Biosimilar Bevacizuma Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Avastin

Table 4. Major Players of Mvasi

Table 5. Major Players of Zirabev

Table 6. Major Players of Aybintio

Table 7. Major Players of Others

Table 8. Global Biosimilar Bevacizuma Sales by Type (2021-2026) & (K Dose)

Table 9. Global Biosimilar Bevacizuma Sales Market Share by Type (2021-2026)

Table 10. Global Biosimilar Bevacizuma Revenue by Type (2021-2026) & (\$ million)

Table 11. Global Biosimilar Bevacizuma Revenue Market Share by Type (2021-2026)

Table 12. Global Biosimilar Bevacizuma Sale Price by Type (2021-2026) & (US\$/Dose)

Table 13. Global Biosimilar Bevacizuma Sale by Application (2021-2026) & (K Dose)

Table 14. Global Biosimilar Bevacizuma Sale Market Share by Application (2021-2026)

Table 15. Global Biosimilar Bevacizuma Revenue by Application (2021-2026) & (\$ million)

Table 16. Global Biosimilar Bevacizuma Revenue Market Share by Application (2021-2026)

Table 17. Global Biosimilar Bevacizuma Sale Price by Application (2021-2026) & (US\$/Dose)

Table 18. Global Biosimilar Bevacizuma Sales by Company (2021-2026) & (K Dose)

Table 19. Global Biosimilar Bevacizuma Sales Market Share by Company (2021-2026)

Table 20. Global Biosimilar Bevacizuma Revenue by Company (2021-2026) & (\$ millions)

Table 21. Global Biosimilar Bevacizuma Revenue Market Share by Company (2021-2026)

Table 22. Global Biosimilar Bevacizuma Sale Price by Company (2021-2026) & (US\$/Dose)

Table 23. Key Manufacturers Biosimilar Bevacizuma Producing Area Distribution and Sales Area

Table 24. Players Biosimilar Bevacizuma Products Offered

Table 25. Biosimilar Bevacizuma Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 26. New Products and Potential Entrants

Table 27. Market M&A Activity & Strategy

Table 28. Global Biosimilar Bevacizuma Sales by Geographic Region (2021-2026) & (K Dose)

Table 29. Global Biosimilar Bevacizuma Sales Market Share Geographic Region (2021-2026)

Table 30. Global Biosimilar Bevacizuma Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 31. Global Biosimilar Bevacizuma Revenue Market Share by Geographic Region (2021-2026)

Table 32. Global Biosimilar Bevacizuma Sales by Country/Region (2021-2026) & (K Dose)

Table 33. Global Biosimilar Bevacizuma Sales Market Share by Country/Region (2021-2026)

Table 34. Global Biosimilar Bevacizuma Revenue by Country/Region (2021-2026) & (\$ millions)

Table 35. Global Biosimilar Bevacizuma Revenue Market Share by Country/Region (2021-2026)

Table 36. Americas Biosimilar Bevacizuma Sales by Country (2021-2026) & (K Dose)

Table 37. Americas Biosimilar Bevacizuma Sales Market Share by Country (2021-2026)

Table 38. Americas Biosimilar Bevacizuma Revenue by Country (2021-2026) & (\$ millions)

Table 39. Americas Biosimilar Bevacizuma Sales by Type (2021-2026) & (K Dose)

Table 40. Americas Biosimilar Bevacizuma Sales by Application (2021-2026) & (K Dose)

Table 41. APAC Biosimilar Bevacizuma Sales by Region (2021-2026) & (K Dose)

Table 42. APAC Biosimilar Bevacizuma Sales Market Share by Region (2021-2026)

Table 43. APAC Biosimilar Bevacizuma Revenue by Region (2021-2026) & (\$ millions)

Table 44. APAC Biosimilar Bevacizuma Sales by Type (2021-2026) & (K Dose)

Table 45. APAC Biosimilar Bevacizuma Sales by Application (2021-2026) & (K Dose)

Table 46. Europe Biosimilar Bevacizuma Sales by Country (2021-2026) & (K Dose)

Table 47. Europe Biosimilar Bevacizuma Revenue by Country (2021-2026) & (\$ millions)

Table 48. Europe Biosimilar Bevacizuma Sales by Type (2021-2026) & (K Dose)

Table 49. Europe Biosimilar Bevacizuma Sales by Application (2021-2026) & (K Dose)

Table 50. Middle East & Africa Biosimilar Bevacizuma Sales by Country (2021-2026) & (K Dose)

Table 51. Middle East & Africa Biosimilar Bevacizuma Revenue Market Share by Country (2021-2026)

Table 52. Middle East & Africa Biosimilar Bevacizuma Sales by Type (2021-2026) & (K Dose)
Table 53. Middle East & Africa Biosimilar Bevacizuma Sales by Application (2021-2026) & (K Dose)
Table 54. Key Market Drivers & Growth Opportunities of Biosimilar Bevacizuma
Table 55. Key Market Challenges & Risks of Biosimilar Bevacizuma
Table 56. Key Industry Trends of Biosimilar Bevacizuma
Table 57. Biosimilar Bevacizuma Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Biosimilar Bevacizuma Distributors List
Table 60. Biosimilar Bevacizuma Customer List
Table 61. Global Biosimilar Bevacizuma Sales Forecast by Region (2027-2032) & (K Dose)
Table 62. Global Biosimilar Bevacizuma Revenue Forecast by Region (2027-2032) & (\$ millions)
Table 63. Americas Biosimilar Bevacizuma Sales Forecast by Country (2027-2032) & (K Dose)
Table 64. Americas Biosimilar Bevacizuma Annual Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 65. APAC Biosimilar Bevacizuma Sales Forecast by Region (2027-2032) & (K Dose)
Table 66. APAC Biosimilar Bevacizuma Annual Revenue Forecast by Region (2027-2032) & (\$ millions)
Table 67. Europe Biosimilar Bevacizuma Sales Forecast by Country (2027-2032) & (K Dose)
Table 68. Europe Biosimilar Bevacizuma Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 69. Middle East & Africa Biosimilar Bevacizuma Sales Forecast by Country (2027-2032) & (K Dose)
Table 70. Middle East & Africa Biosimilar Bevacizuma Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 71. Global Biosimilar Bevacizuma Sales Forecast by Type (2027-2032) & (K Dose)
Table 72. Global Biosimilar Bevacizuma Revenue Forecast by Type (2027-2032) & (\$ millions)
Table 73. Global Biosimilar Bevacizuma Sales Forecast by Application (2027-2032) & (K Dose)
Table 74. Global Biosimilar Bevacizuma Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 75. Amgen Basic Information, Biosimilar Bevacizuma Manufacturing Base, Sales Area and Its Competitors

Table 76. Amgen Biosimilar Bevacizuma Product Portfolios and Specifications

Table 77. Amgen Biosimilar Bevacizuma Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 78. Amgen Main Business

Table 79. Amgen Latest Developments

Table 80. AryoGen Basic Information, Biosimilar Bevacizuma Manufacturing Base, Sales Area and Its Competitors

Table 81. AryoGen Biosimilar Bevacizuma Product Portfolios and Specifications

Table 82. AryoGen Biosimilar Bevacizuma Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 83. AryoGen Main Business

Table 84. AryoGen Latest Developments

Table 85. Pharmed Basic Information, Biosimilar Bevacizuma Manufacturing Base, Sales Area and Its Competitors

Table 86. Pharmed Biosimilar Bevacizuma Product Portfolios and Specifications

Table 87. Pharmed Biosimilar Bevacizuma Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 88. Pharmed Main Business

Table 89. Pharmed Latest Developments

Table 90. Biothera Basic Information, Biosimilar Bevacizuma Manufacturing Base, Sales Area and Its Competitors

Table 91. Biothera Biosimilar Bevacizuma Product Portfolios and Specifications

Table 92. Biothera Biosimilar Bevacizuma Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 93. Biothera Main Business

Table 94. Biothera Latest Developments

Table 95. Boehringer Ingelheim Basic Information, Biosimilar Bevacizuma Manufacturing Base, Sales Area and Its Competitors

Table 96. Boehringer Ingelheim Biosimilar Bevacizuma Product Portfolios and Specifications

Table 97. Boehringer Ingelheim Biosimilar Bevacizuma Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 98. Boehringer Ingelheim Main Business

Table 99. Boehringer Ingelheim Latest Developments

Table 100. Centus Biotherapeutics Basic Information, Biosimilar Bevacizuma Manufacturing Base, Sales Area and Its Competitors

Table 101. Centus Biotherapeutics Biosimilar Bevacizuma Product Portfolios and

Specifications

Table 102. Centus Biotherapeutics Biosimilar Bevacizuma Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 103. Centus Biotherapeutics Main Business

Table 104. Centus Biotherapeutics Latest Developments

Table 105. Henlius Biotech Basic Information, Biosimilar Bevacizuma Manufacturing Base, Sales Area and Its Competitors

Table 106. Henlius Biotech Biosimilar Bevacizuma Product Portfolios and Specifications

Table 107. Henlius Biotech Biosimilar Bevacizuma Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 108. Henlius Biotech Main Business

Table 109. Henlius Biotech Latest Developments

Table 110. Innovent Biologics Basic Information, Biosimilar Bevacizuma Manufacturing Base, Sales Area and Its Competitors

Table 111. Innovent Biologics Biosimilar Bevacizuma Product Portfolios and Specifications

Table 112. Innovent Biologics Biosimilar Bevacizuma Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 113. Innovent Biologics Main Business

Table 114. Innovent Biologics Latest Developments

Table 115. Mylan Basic Information, Biosimilar Bevacizuma Manufacturing Base, Sales Area and Its Competitors

Table 116. Mylan Biosimilar Bevacizuma Product Portfolios and Specifications

Table 117. Mylan Biosimilar Bevacizuma Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 118. Mylan Main Business

Table 119. Mylan Latest Developments

Table 120. mAbxience Basic Information, Biosimilar Bevacizuma Manufacturing Base, Sales Area and Its Competitors

Table 121. mAbxience Biosimilar Bevacizuma Product Portfolios and Specifications

Table 122. mAbxience Biosimilar Bevacizuma Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 123. mAbxience Main Business

Table 124. mAbxience Latest Developments

Table 125. Outlook Therapeutics Basic Information, Biosimilar Bevacizuma Manufacturing Base, Sales Area and Its Competitors

Table 126. Outlook Therapeutics Biosimilar Bevacizuma Product Portfolios and Specifications

Table 127. Outlook Therapeutics Biosimilar Bevacizuma Sales (K Dose), Revenue (\$

Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 128. Outlook Therapeutics Main Business

Table 129. Outlook Therapeutics Latest Developments

Table 130. Pfizer Basic Information, Biosimilar Bevacizuma Manufacturing Base, Sales Area and Its Competitors

Table 131. Pfizer Biosimilar Bevacizuma Product Portfolios and Specifications

Table 132. Pfizer Biosimilar Bevacizuma Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 133. Pfizer Main Business

Table 134. Pfizer Latest Developments

Table 135. Prestige Biopharma Basic Information, Biosimilar Bevacizuma Manufacturing Base, Sales Area and Its Competitors

Table 136. Prestige Biopharma Biosimilar Bevacizuma Product Portfolios and Specifications

Table 137. Prestige Biopharma Biosimilar Bevacizuma Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 138. Prestige Biopharma Main Business

Table 139. Prestige Biopharma Latest Developments

Table 140. Roche Basic Information, Biosimilar Bevacizuma Manufacturing Base, Sales Area and Its Competitors

Table 141. Roche Biosimilar Bevacizuma Product Portfolios and Specifications

Table 142. Roche Biosimilar Bevacizuma Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 143. Roche Main Business

Table 144. Roche Latest Developments

Table 145. Samsung Bio Basic Information, Biosimilar Bevacizuma Manufacturing Base, Sales Area and Its Competitors

Table 146. Samsung Bio Biosimilar Bevacizuma Product Portfolios and Specifications

Table 147. Samsung Bio Biosimilar Bevacizuma Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 148. Samsung Bio Main Business

Table 149. Samsung Bio Latest Developments

Table 150. TOT Biopharm Basic Information, Biosimilar Bevacizuma Manufacturing Base, Sales Area and Its Competitors

Table 151. TOT Biopharm Biosimilar Bevacizuma Product Portfolios and Specifications

Table 152. TOT Biopharm Biosimilar Bevacizuma Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 153. TOT Biopharm Main Business

Table 154. TOT Biopharm Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Biosimilar Bevacizuma
- Figure 2. Biosimilar Bevacizuma Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Biosimilar Bevacizuma Sales Growth Rate 2021-2032 (K Dose)
- Figure 7. Global Biosimilar Bevacizuma Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Biosimilar Bevacizuma Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Biosimilar Bevacizuma Sales Market Share by Country/Region (2025)
- Figure 10. Biosimilar Bevacizuma Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Avastin
- Figure 12. Product Picture of Mvasi
- Figure 13. Product Picture of Zirabev
- Figure 14. Product Picture of Aybintio
- Figure 15. Product Picture of Others
- Figure 16. Global Biosimilar Bevacizuma Sales Market Share by Type in 2026
- Figure 17. Global Biosimilar Bevacizuma Revenue Market Share by Type (2021-2026)
- Figure 18. Biosimilar Bevacizuma Consumed in Colorectal Cancer
- Figure 19. Global Biosimilar Bevacizuma Market: Colorectal Cancer (2021-2026) & (K Dose)
- Figure 20. Biosimilar Bevacizuma Consumed in Non-Small Cell Lung Cancer
- Figure 21. Global Biosimilar Bevacizuma Market: Non-Small Cell Lung Cancer (2021-2026) & (K Dose)
- Figure 22. Biosimilar Bevacizuma Consumed in Glioblastoma
- Figure 23. Global Biosimilar Bevacizuma Market: Glioblastoma (2021-2026) & (K Dose)
- Figure 24. Biosimilar Bevacizuma Consumed in Renal Cell Carcinoma
- Figure 25. Global Biosimilar Bevacizuma Market: Renal Cell Carcinoma (2021-2026) & (K Dose)
- Figure 26. Biosimilar Bevacizuma Consumed in Cervical Cancer
- Figure 27. Global Biosimilar Bevacizuma Market: Cervical Cancer (2021-2026) & (K Dose)
- Figure 28. Biosimilar Bevacizuma Consumed in Ovarian Cancer
- Figure 29. Global Biosimilar Bevacizuma Market: Ovarian Cancer (2021-2026) & (K

Dose)

Figure 30. Biosimilar Bevacizuma Consumed in Others

Figure 31. Global Biosimilar Bevacizuma Market: Others (2021-2026) & (K Dose)

Figure 32. Global Biosimilar Bevacizuma Sale Market Share by Application (2025)

Figure 33. Global Biosimilar Bevacizuma Revenue Market Share by Application in 2026

Figure 34. Biosimilar Bevacizuma Sales by Company in 2026 (K Dose)

Figure 35. Global Biosimilar Bevacizuma Sales Market Share by Company in 2026

Figure 36. Biosimilar Bevacizuma Revenue by Company in 2026 (\$ millions)

Figure 37. Global Biosimilar Bevacizuma Revenue Market Share by Company in 2026

Figure 38. Global Biosimilar Bevacizuma Sales Market Share by Geographic Region (2021-2026)

Figure 39. Global Biosimilar Bevacizuma Revenue Market Share by Geographic Region in 2026

Figure 40. Americas Biosimilar Bevacizuma Sales 2021-2026 (K Dose)

Figure 41. Americas Biosimilar Bevacizuma Revenue 2021-2026 (\$ millions)

Figure 42. APAC Biosimilar Bevacizuma Sales 2021-2026 (K Dose)

Figure 43. APAC Biosimilar Bevacizuma Revenue 2021-2026 (\$ millions)

Figure 44. Europe Biosimilar Bevacizuma Sales 2021-2026 (K Dose)

Figure 45. Europe Biosimilar Bevacizuma Revenue 2021-2026 (\$ millions)

Figure 46. Middle East & Africa Biosimilar Bevacizuma Sales 2021-2026 (K Dose)

Figure 47. Middle East & Africa Biosimilar Bevacizuma Revenue 2021-2026 (\$ millions)

Figure 48. Americas Biosimilar Bevacizuma Sales Market Share by Country in 2026

Figure 49. Americas Biosimilar Bevacizuma Revenue Market Share by Country (2021-2026)

Figure 50. Americas Biosimilar Bevacizuma Sales Market Share by Type (2021-2026)

Figure 51. Americas Biosimilar Bevacizuma Sales Market Share by Application (2021-2026)

Figure 52. United States Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 53. Canada Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 54. Mexico Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 55. Brazil Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 56. APAC Biosimilar Bevacizuma Sales Market Share by Region in 2026

Figure 57. APAC Biosimilar Bevacizuma Revenue Market Share by Region (2021-2026)

Figure 58. APAC Biosimilar Bevacizuma Sales Market Share by Type (2021-2026)

Figure 59. APAC Biosimilar Bevacizuma Sales Market Share by Application (2021-2026)

Figure 60. China Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 61. Japan Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 62. South Korea Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 63. Southeast Asia Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 64. India Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 65. Australia Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 66. China Taiwan Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 67. Europe Biosimilar Bevacizuma Sales Market Share by Country in 2026

Figure 68. Europe Biosimilar Bevacizuma Revenue Market Share by Country (2021-2026)

Figure 69. Europe Biosimilar Bevacizuma Sales Market Share by Type (2021-2026)

Figure 70. Europe Biosimilar Bevacizuma Sales Market Share by Application (2021-2026)

Figure 71. Germany Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 72. France Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 73. UK Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 74. Italy Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 75. Russia Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 76. Middle East & Africa Biosimilar Bevacizuma Sales Market Share by Country (2021-2026)

Figure 77. Middle East & Africa Biosimilar Bevacizuma Sales Market Share by Type (2021-2026)

Figure 78. Middle East & Africa Biosimilar Bevacizuma Sales Market Share by Application (2021-2026)

Figure 79. Egypt Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 80. South Africa Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 81. Israel Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 82. Turkey Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 83. GCC Countries Biosimilar Bevacizuma Revenue Growth 2021-2026 (\$ millions)

Figure 84. Manufacturing Cost Structure Analysis of Biosimilar Bevacizuma in 2026

Figure 85. Manufacturing Process Analysis of Biosimilar Bevacizuma

Figure 86. Industry Chain Structure of Biosimilar Bevacizuma

Figure 87. Channels of Distribution

Figure 88. Global Biosimilar Bevacizuma Sales Market Forecast by Region (2027-2032)

Figure 89. Global Biosimilar Bevacizuma Revenue Market Share Forecast by Region (2027-2032)

Figure 90. Global Biosimilar Bevacizuma Sales Market Share Forecast by Type (2027-2032)

Figure 91. Global Biosimilar Bevacizuma Revenue Market Share Forecast by Type (2027-2032)

Figure 92. Global Biosimilar Bevacizuma Sales Market Share Forecast by Application (2027-2032)

Figure 93. Global Biosimilar Bevacizuma Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Biosimilar Bevacizuma Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/GFA4185551B2EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GFA4185551B2EN.html>